OptimizeRx Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $109.4M+18.8% YoYTTM through 30 Jun 2026
Net Income $4.6MTTM through 30 Jun 2026
Free Cash Flow $18.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 75.2% |
| EBITDA Margin | 13.9% |
| Operating Margin | 2.0% |
| Net Margin | 4.2% |
Returns
5.3%ROE
-0.3%ROA
3.7%ROIC
Balance Sheet Health
Debt / Equity0.18x
Current Ratio5.37x
Net Debt$3.2M
Cash & Equivalents$24.1M
Quality Metrics
Altman Z-Score3.12
Piotroski F-Score8 / 9
FCF Margin16.8%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $109.4M
Diluted EPS$0.25TTMFY2025: $0.27
Dividend
No dividend
Capital Allocation
R&D Spend$332K
Capex Intensity0.1%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.